Please assess the completion status of the following clinical trial:

Trial Title: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, age greater than or equal to 45 years at the time of signing informed consent~* Body mass index (BMI) greater than or equal to 27 kg/m\^2~* Have established cardiovascular (CV) disease as evidenced by at least one of the following: prior myocardial infarction; prior stroke (ischemic or haemorrhagic stroke); or symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease~Exclusion Criteria:~Cardiovascular-related:~* Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening~* Presently classified as being in New York Heart Association (NYHA) Class IV heart failure~Glycaemia-related:~* HbA1c greater than or equal to 48 mmol/mol (6.5 %) as measured by the central laboratory at screening~* History of type 1 or type 2 diabetes (history of gestational diabetes is allowed)~* Treatment with glucose-lowering agents within 90 days before screening~* Treatment with any glucagon-like-peptide-1 receptor agonist (GLP-1 RA) within 90 days before screening~General safety:~* History or presence of chronic pancreatitis~* Presence of acute pancreatitis within the past 180 days prior to the day of screening~* Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma~* End stage renal disease or chronic or intermittent haemodialysis or peritoneal dialysis~* Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed~* Severe psychiatric disorder which in the investigator's opinion could compromise compliance with the protocol~* Known or suspected hypersensitivity to trial products or related products~* Previous participation in this trial. Participation is defined as randomisation~* Receipt of any investigational medicinal product within 30 days before screening~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method~* Any disorder, unwillingness or inability, which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).